Within three months, all previous gains were given back. Can "Double Eleven" help GIANT BIOGENE (02367) stage a stock price comeback?

Thanks to the expectation repair brought about by "the 618 recovery + the landing of the medical aesthetics matrix," GIANT BIOGENE's (02367) stock price staged a clear rally between July 10 and July 29 this year, with a gain of 23.11% during the period, pushing the stock price back above HK$30. Although over the following three months, under the influence of multiple factors, its stock price gave back the earlier gains, now that the "Double Eleven" event is about to begin, more investors' attention is once again focusing on this Hong Kong-listed medical aesthetics leader. After giving back earlier gains, entering a low-level repair phase It has been observed that since July 10 this year, GIANT BIOGENE's stock price has shown an "inverted V" pattern. During the rally phase from July 10 to July 29, GIANT BIOGENE's stock price showed a three-stage trend acceleration on the chart. Among this, within the four trading days from July 10 to 16, the company's stock price rose by a cumulative 13.8%. Along with the stock price rise, GIANT BIOGENE's trading volume on July 10 reached 8.2226 million shares, 1.71 times its previous 5-day average volume, and continued to expand on July 16 to 9.0327 million shares, overall showing a healthy trend of rising volume and price together. Although there was a period of shrinking-volume consolidation from July 17 to 28, the company's stock price retraced relatively little within that range, fluctuating narrowly only between HK$29.00 and HK$29.60; then on July 29, GIANT BIOGENE's stock price gapped up and finally closed up 7.27%, and during intraday trading that day hit a stage high of HK$31.40, completing this three-stage acceleration. Within the above range, GIANT BIOGENE not only achieved rising volume and price together on the chart, but its technical momentum and trend strength also rose in sync: while the moving averages were in a perfect bullish alignment, the MACD indicator completed a golden cross below the zero line and then formed a bullish alignment above it; the ADX indicator rose all the way from 25 on July 10 to 43.7 on July 29, signaling that within this range, the stock's trend strength upgraded from "tradable" to "strong trend." At the same time, during the rally phase, the company's stock price basically ran along the upper rail of the BOLL band, and the BOLL bandwidth expanded significantly by 24.6%, showing that during this phase GIANT BIOGENE's stock price volatility rose in tandem with trend acceleration. However, a sharp rally in a short period of time is inevitably accompanied by short-term overheating in the stock price. During this stock price rally in GIANT BIOGENE, the RSI indicator rushed straight from the neutral range of 52.8 to the overbought zone of 82.1, indicating obvious short-term overheating; while although the KDJ indicator rose after a low-level golden cross, the J value fell back after touching 110 around July 16, the first stage of the volume-driven launch, indicating that at that time there may have been demand for a pullback after high-level. As GIANT BIOGENE's stock price on July 29 reached the end of the acceleration phase of this round of gains, the short-term overheated technical signals became the trigger for its correction. In addition, regarding industry and company fundamentals, although previously under the positive catalysis of a sector-wide recovery in medical aesthetics and the 618 sales report, GIANT BIOGENE's stock price rose considerably, it is undeniable that the medical aesthetics industry's problems of "tighter regulation, more rational consumption, and intensifying supply competition" have still not been completely reversed. Coupled with the fact that high-growth expectations were revised down by the 26H1 financial report, triggering periodic market sentiment fluctuations, GIANT BIOGENE's stock price gave back all of its earlier gains over the following three months. It has been observed that under the joint guidance of technicals and fundamentals, GIANT BIOGENE's stock price saw a volume-driven decline in mid-August and entered its main decline phase, only beginning to repair after probing a low of HK$22.40 intraday on October 7. At that time, the company's stock price had already suffered a maximum drawdown of 26.58% from its previous high. However, as the "Double Eleven" event approaches, market sentiment has also begun to shift from consensus to divergence, with some investors starting to trade the potential benefits that this second major consumption event after the "618" event may bring to GIANT BIOGENE. Can "Double Eleven" ignite market sentiment again? Although GIANT BIOGENE's stock price continued to be in a downward range after July 30, on October 9 it rose 4.47% on increased volume, with trading volume that day expanding to 2.5 times the previous 5-day average. Even though it fell again the next day, closing down 3.27%, trading volume that day was still about 2.05 times the previous 5-day average. This volume-price signal may be conveying an important message to the market, namely that the low-level divergence in GIANT BIOGENE's current trading may be gradually widening. And the important variable triggering this phenomenon is the recent "Double Eleven" event. As mentioned above, among the logics supporting GIANT BIOGENE's stock price rise from July 10 to July 29, the recovery in the "618" event sales report was an important factor. According to the company's disclosed 618 promotional sales report: Comfy's online all-channel GMV increased by more than 25% year-on-year, and Collgene's full-cycle GMV increased by more than 30% year-on-year. According to Huachuang Securities' research report analysis, even though affected by the downward revision in performance, after comprehensive consideration it still assigned GIANT BIOGENE's 2026 cosmetics business a 15x PE, or a market value of RMB 29 billion; plus a potential medical aesthetics market value increment of RMB 6 billion, for a total target market value of RMB 35 billion. Accordingly, Huachuang Securities at that time gave GIANT BIOGENE a target price of HK$38.01. From a valuation perspective, after more than two months of stock price decline, GIANT BIOGENE's PE valuation at this time is only 12.78x, already below the industry average PE of 13.73x, also leaving room for possible subsequent stock price growth. Among the highlights of the "Double Eleven" event, in addition to observing the event sales report data, investors also need to pay attention to the S+-level new product Ultra Pen of the Comfy Focus series launched by GIANT BIOGENE in April this year. This product's self-operated GMV exceeded RMB 30 million in its first week on the market and surpassed RMB 100 million within 100 days of launch, and institutions estimate it will contribute about RMB 200 million in revenue for the full year. This "Double Eleven" sales performance may, to a certain extent, verify whether it can serve as a "strategic relay product" after GIANT BIOGENE's major single product Collagen Stick, thereby directly determining whether the market believes the company can switch from a "single hit product dependence" to a "product matrix-driven" logic. In addition, expectations of a fundamental inflection point are also driving on-market and off-market investors to speculate on GIANT BIOGENE's medium- to long-term outlook. It is understood that with the approval in January of the world's first injectable recombinant collagen and sodium hyaluronate composite solution, the approval in June this year of the world's first cross-linked recombinant type III collagen implant for neck wrinkle filling, and the 753 collagen needle that officially launched in June this year, GIANT BIOGENE currently already holds 4 Class III medical device (881144) registration certificates. Whether it can prove to investors in subsequent financial reports that it has moved from a "registration certificate story" into a "commercialization realization period" and opened a second growth curve for its medical aesthetics business will also become an important factor affecting GIANT BIOGENE's future valuation upward revision.